Innovative drug could help treat acute organ injury

9 November 2020

A newly-inked licensing deal will see Switzerland-based Vifor Pharma (VTX: VIFN) pick up certain rights to ANG-3777 from San Francisco, USA Angion Biomedica.

The small molecule is designed to mimic the biological activity of hepatocyte growth factor (HGF), but with a much longer half-life.

Currently under development for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury, the firms think it has the potential to be a first-in-class therapeutic addressing acute organ injury.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK